Table 1

	Present series. Flores Robles et al.	Martínez et al.	Díaz-Lagares et al.	Zmuda et al.	Khan et al.	Díaz-Llopis et al.	Nicolli et al.	Jeroudis et al.	Díaz-Llopis et al.	Yosuf et al.

	Spain	Spain (2)	Spain (3)	France (4)	USA (5)	Spain (6)	Italy (7)	USA (8)	Spain (9)	USA (10)

Number of Cases	2	3	4	2	2	1	2	1	8	2
Age (mean in years)	43.5	40	Not specified (NS)	35.5	14.5	36	39.5	15	NS	11
Previous immunosuppressive or biologic	CYA and AZA	MTX (2 cases)	CyS (4 cases)	MTX	MTX (1 case)	CyS	AZA (2 cases)	MTX	NS	MTX (2 cases)
		CyS (3 cases)	MTX (2 cases)		CyS (1 case)		CyS (2 cases)			MMF (1 case)
			AZA (1 case)		Tacrolimus (1 case)					CyS (1 case)
					AZA (1 case)
					MMF (1 case)
Biologic used	IFX (n=2), ADA (n=2)	IFX	ADA	IFX	IFX	ADA	IFX	ADA	IFX	IFX
Reason for initiating anti-TNFα	Immunosuppressant failure (IF)	IF	IF	First-line	IF	CyS failure	IF	MTXfailure	IF	First-line
Patients with clinical response	2	3	3	2	2	1	2	1	8	1
Adverse effects due to anti-TNFα	1	None	None	(1 case)	None	None	None	None	Not specified	None
Duration of response	18 months	Not specified	9.5 months	7 months	17 months	8 months	27 months	26 months	NS	12 months (1 patient)